Firering Strategic Minerals: From explorer to producer. Watch the video here.
Well put Luton the granting of the US Patent for SDC-1802 now means 1801 or 1802 can be licensed independently and any Suitor considering a takeover now risks Sareums value rising exponentially with a Covid-19 Grant, SRA737 resumption/on-license and FLT3 Aurora license.
Exciting times lay ahead Its Sars time to shine GLA
No top slicing for me, I'm fortunate enough to be able to let this one run until both our TYK2's sing and if they are as good as we all hope they are Sareum will be swallowed up by a Major Pharma at some point in the future.........
GLA It's Sars time to shine
Sareum intends to make grant applications to explore the activity of SDC-1801 in COVID-19, where the aim would be to reduce the immune system over-reaction that has been seen in the later phase of the infection. If such grant applications are awarded, SDC-1801 could join a group of drugs – including a number of JAK inhibitors – that have been fast-tracked into trials for COVID-19 As a dual TYK2/JAK1 inhibitor, SDC-1801 could be more effective and/or better tolerated than these similar compounds in treating COVID-19.
Just when you thought the day couldn't get any better more fantastic news for Sareum and step up our TYK2/Jak1 SDC-1801
Baricitinib has Significant Effect on Recovery Time, Most Impactful in COVID-19 Patients Requiring Oxygen.
https://newsfilter.io/a/1bfc907a5e2580d7ccf6073faf5d4328
Take a look at the Black Box warnings for Olumiant (baricitinib)
Absolutely Fantastic Patent News and will seal a deal :)
Upcoming RNS's:
TYK2 Covid-19 potential UKRI grant approval (Due Anytime Oct)
TYK2 Further grant applications for Covid-19 research (Due Anytime Q4)
TYK2 Updates on preclinical (IND-enabling) tox studies (Due Anytime Q4)
TYK2 Journal paper on preclinical studies (SDC-1802 vs. solid tumours) (Due Anytime Q4)
TYK2 SDC-1801 Potential IND Submission (Q4 2020)
TYK2 Late pre-clinical licence deals (Anytime $$$$$$$$$$$$)
SRA737 Clarity on future development funding & plans (Due Anytime)
SRA737 Final Data readouts from 2 completed clinical studies (Due Anytime Q4)
SRA737 Potential next milestone payment ($5.4m to Sareum)
FLT3 Update on formulation success (Due Anytime before Jan 8th Q1*)
FLT3 Potential milestone payments+ (Potential Early Announcement*)
Thanks for the Link B - The Bod sounding bullish on SRA737 and nice to see confirmation from them that the trials have been completed /
"SRA737 is emerging as the potential class leader, and has completed two Phase 2 studies"
"SRA737 demonstrated <33% tumour shrinkage in 30% of evaluable anogenital cancer patients, and stable disease in a further 30%. Anogenital cancer is a clear unmet medical need, with no second-line therapies available"
Ducks lining up nicely for a bumper Xmas GLA
Dates Match
FLT3+Aurora Inhibitors The Licensee (a China-based specialty pharmaceutical company) confirmed receipt of the programme data on 7 April 2020
2020-04-07 Application filed by SAREUM Ltd
2020-04-07 Priority to GBGB2005114.0A
2020-05-20 Publication of GB202005114D0
Status Pending
CHK1 Colorectal Cancer
Article September 22, 2020
https://www.cell.com/cell-reports/fulltext/S2211-1247(20)31173-6
Pdf: https://www.cell.com/cell-reports/pdf/S2211-1247(20)31173-6.pdf
We find that BRAFV600E-mutant cancer cells and organoids are sensitive to combinations of Chk1 inhibitors and chemically induced replication stress, pointing toward future therapeutic approaches exploiting nuclear vulnerabilities induced by BRAFV600E. Our data therefore support a specific role of Chk1 in exploiting replication stress-driven vulnerabilities in BRAF-driven cancer.
Nothing is priced into the SP for SRA737 or Aurora + FLT3 both are out of our bods control and we will only hear news when its time and this can drop anytime, frustrating for some but focus should be on the main prize ;)
As for our TYK2’s you never know we may get a nice preclinical progress and MTD update next week //// GLA
This article gives a good overview of the current landscape and the direction of travel for SRA737 you can also see in figure 2 Merck’s M4344 which helps to understand the recent link to the combination of M4344 & SRA737 https://cancerres.aacrjournals.org/content/80/16_Supplement/LB-121 amongst others.
Thanks Matador seems appropriate to add this here (couple of mentions of SRA737)
Advances in synthetic lethality for cancer therapy: cellular mechanism and clinical translation
Published 3rd Sep 2020 https://jhoonline.biomedcentral.com/articles/10.1186/s13045-020-00956-5
The future will be managing toxicities in combination therapies / This is where SRA737 will shine through
Exciting times ahead GLA
Roll Up SDC-1802
Currently, there are no virus-specific treatments for HPV infection or HPV-associated cancers. Thus, new treatment strategies are required, and the JAK/STAT pathway offers a potential novel therapeutic avenue. As both STAT3 and STAT5 are implicated in HPV infection and HPV-associated cancers, the inhibition of these pathways may inhibit viral replication and be beneficial in the prevention or treatment of these cancers.
These studies suggest that the targeting of JAKs may have clinical benefit in many solid tumours, including HPV+ cancers.
https://www.mdpi.com/1999-4915/12/9/977
Always that possibility Potnak although it would be a way away Q2 next year best guess, a point to note as previously stated by our Bod it would be SDC-1802 that would be entered into a small P1 so the costs wouldn’t be massive and if proof of concept was achieved the rewards would be well massive.
Lots of game changing news due sit back relax and enjoy the ride GLA
J4F I would be inclined to go by the EU register as follows:
SRA737-01 End of Trial Status - Completed – Date of Global end of trial 28th October 2019 (Bottom of Page) - https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004486-86/GB
SRA737-02 End of Trial Status - Completed – Date of Global end of trial 8th April 2020 (Bottom of Page) - https://www.clinicaltrialsregister.eu/ctr-search/trial/2015-004467-36/GB
8th April is pretty much a match from Tims Proactive Interview on the 31st March which leads me to believe is most probably accurate and the date used for the Final Data Readouts which we are expecting Sierra to publish soon (H2 2020) It’s possible that some are still receiving benefit as why the ClinicalTrials.gov is still showing active https://clinicaltrials.gov/ct2/show/NCT02797977
As for "This trial has been completed in Austria according to European Clinical Trials Database record) https://adisinsight.springer.com/trials/700273096 No idea; misprint for Spain or anyone’s guess.
It might all look a bit of a mucking fuddle but it will come out in the wash at some point in the near future GL